Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    TED11746
Show Display Options
Rank Status Study
1 Completed A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
Condition: Neoplasm Malignant
Interventions: Drug: Iniparib (SAR240550-BSI-201);   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Placlitaxel;   Drug: Pegylated liposomal doxorubicin

Indicates status has not been verified in more than two years